Multiple Myeloma — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:Introduction (0:00)Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Ma...
18 Kesä 47min
Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:Introduction (0:00)Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)No...
16 Kesä 55min
Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:Introduction (0:00)Antibody-Drug Conjugates and Other Novel Strategies for the Managem...
15 Kesä 1h 59min
Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advance...
23 Touko 58min
Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data sur...
20 Huhti 58min
CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of...
10 Huhti 24min
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antag...
1 Huhti 24min
CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of...
23 Maalis 24min
